Sign In
Buy SPRY
$8.75
-0.150 (-1.69%)
At Close: Jun 03, 2026
ARS Pharmaceuticals: Still A Buy As Neffy Access Improves
05:27am, Wednesday, 20'th May 2026
ARS Pharmaceuticals is now focused on scaling Neffy. This is their needle-free epinephrine spray for severe allergic reactions, and it's also core to my bull case on SPRY. Recently, we've seen SPRY do
ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call Transcript
09:30pm, Friday, 15'th May 2026
ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call Transcript
ARS Pharmaceuticals Q1 Earnings Call Highlights
12:11pm, Friday, 15'th May 2026
ARS Pharmaceuticals NASDAQ: SPRY reported first-quarter 2026 revenue of $22.7 million as executives said the company is working to expand access, reduce prescribing friction and build momentum for nef
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates
08:12am, Friday, 15'th May 2026
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.35 per share a year ago.
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
06:00am, Friday, 15'th May 2026
Q1 2026 total revenue of $22.7 million including neffy ® (epinephrine nasal spray) U.S. net product revenue of $17.5 million
ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
02:08am, Friday, 15'th May 2026
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) will release earnings for its first quarter before the opening bell on Friday, May 15.
ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President
08:00am, Wednesday, 13'th May 2026
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering patients and their caregivers to better protect against severe
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results
08:00am, Thursday, 07'th May 2026
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patien
Earnings Preview: ARS Pharmaceuticals, Inc. (SPRY) Q1 Earnings Expected to Decline
11:01am, Wednesday, 06'th May 2026
ARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ARS Pharmaceuticals, Inc. (SPRY) Soars 7.1%: Is Further Upside Left in the Stock?
09:45am, Thursday, 23'rd Apr 2026
ARS Pharmaceuticals, Inc. (SPRY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further pr
neffy offers a new delivery method for epinephrine in Canada for adults and children ( > 30 kg) living with severe allergic reactions
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label
08:00am, Friday, 27'th Mar 2026
Children were previously required to weigh ≥33 lbs. and
Bamco Inc. NY Buys 1,228,532 Shares of ARS Pharmaceuticals, Inc. $SPRY
04:24am, Monday, 16'th Mar 2026
Bamco Inc. NY grew its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) by 3,071.3% in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investo
ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines
12:38pm, Wednesday, 11'th Mar 2026
ARS Pharmaceuticals, Inc. maintains a Hold rating as neffy's commercial uptake remains slow despite FDA approval and a robust marketing push. SPRY reported 2025 revenues of $84.3m, a net loss of $171.
ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call Transcript
10:58am, Monday, 09'th Mar 2026
ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call Transcript
